bwin±ØÓ®Ò½Ò©ÉÌÒµ»¯Æ½Ì¨ÓÖÌíÐÂÏàÖú£¬£¬£¬£¬£¬ÔÙ¶ÈЯÊÖ°²Ë¹Ì©À´¹²ÍذÐÏòÒ©Èë¿ÚÐÂÆªÕÂ
2020-12-16
12ÔÂ16ÈÕ£¬£¬£¬£¬£¬°²Ë¹Ì©À´ÖÆÒ©£¨Öйú£©ÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°°²Ë¹Ì©À´¡±£©Óëbwin±ØÓ®£¨ÒÔϼò³Æ¡°bwin±ØÓ®Ò½Ò©¡±£©ÔÚ±±¾©¾ÙÐÐÁËXOSPATA?£¨Ó¢ÎÄͨÓÃÃû£ºgilteritinib fumarate tablets£¬£¬£¬£¬£¬ÖÐÎÄͨÓÃÃû£º¸»ÂíËἪÈðÌæÄáÆ¬£¬£¬£¬£¬£¬ÒÔÏÂͳ³ÆÎª¡°XOSPATA¡±£©Èë¿ÚºÍ×ܾÏúÏà¹ØµÄÏàÖúÒâÏòÊéǩԼÒÇʽ¡£¡£¡£Õ⽫µÓڨ˫·½ÔÚÈë¿ÚÒ©ÁìÓòÊ׸ö²úÆ·µÄÏàÖú»ù´¡¡£¡£¡£

ǩԼÒÇʽºÏÓ°
´Ëǰ£¬£¬£¬£¬£¬bwin±ØÓ®Ò½Ò©ÒÑÓ밲˹̩À´¾ÍÆìϵĹþÀֺͷƲ¼Á¦Æ·ÅƸ濢սÂÔÏàÖú£¬£¬£¬£¬£¬ÔÚ¶à¸ö¼²²¡ÁìÓòΪÖйú»¼ÕßÌṩ¿µ½¡Ð§ÀÍ¡£¡£¡£´Ë´ÎË«·½ÔÙ¶ÈЯÊÖ£¬£¬£¬£¬£¬ÐÁ¦ÍƽøXOSPATA½øÈëÖйúÊг¡£¡£¡£¬£¬£¬£¬£¬½«Ìî²¹º£ÄÚÓÉFLT3»ùÒòÍ»±äÄÑÖÎÐÔ»ò¸´·¢ÐÔ¼±ÐÔËèϵ°×Ѫ²¡£¡£¡£¨AML£©»¼ÕßÎÞ»ñÅú°ÐÏòÒ©¿ÉÓõĿÕȱ£¬£¬£¬£¬£¬ÎªAML³ÉÈË»¼Õß´øÀ´ÐµÄÖÎÁƼƻ®¡£¡£¡£
º£ÄÚÊ׸ö¶þ´úFLT3°ÐÏòÒ©£¬£¬£¬£¬£¬½«´øÀ´Í»ÆÆÐÔÖÎÁƼƻ®
¾ÝÏà¹ØÍ³¼Æ£¬£¬£¬£¬£¬ÎÒ¹úÿÄêÔ¼ÓÐ8ÍòÈËÕï¶Ï»¼Óа×Ѫ²¡1£¬£¬£¬£¬£¬¶ø¼±ÐÔËèϵ°×Ѫ²¡£¡£¡£¨AML£©ÊdzÉÄêÈ˳£¼ûµÄ°×Ѫ²¡ÀàÐÍÖ®Ò»2£¬£¬£¬£¬£¬ÊÇÒ»ÖÖ¶ÔѪҺºÍ¹ÇËèÇÖÏ®ÐÔÇ¿¡¢Ï£ÍûѸËٵĶñÐÔÖ×Áö£¬£¬£¬£¬£¬¸Ã¼²²¡ÒÔÔ¤ºó½Ï²î¡¢ÉúÑÄÆÚ¶Ì¡¢ÉúÑÄÂʼ«µÍÖø³Æ£¬£¬£¬£¬£¬ÊÇÈÝÒ׸´·¢µÄÄÑÖβ¡£¡£¡£¬£¬£¬£¬£¬Æä·¢²¡ÂÊËæ×ÅÄêËêµÄÔöÌí¶øÉý¸ß3¡£¡£¡£ÔÚAMLµÄ»¼²¡ÈºÌåÖУ¬£¬£¬£¬£¬ÓÐÔ¼25%¡ª30%µÄ»¼ÕßÓÐFMSÑùÀÒ°±Ëἤø3£¨FLT3£©Í»±äµÄ¿ÉÄÜ£¬£¬£¬£¬£¬¶øº£ÄÚÏÖÔÚ»¹Ã»ÓÐÕë¶ÔFLT3Í»±äÒѱ»»ñÅúÉÏÊеİÐÏòÒ©Îï¡£¡£¡£
×÷Ϊ°²Ë¹Ì©À´µÚÒ»¸öѪҺÖ×ÁöµÄÁ¢ÒìÒ©Î£¬£¬£¬£¬XOSPATA¶ÔFLT3-ITD¼°FLT3-TKD¾ùÓÐÏÔÖøµÄÒÖÖÆ×÷Ó㬣¬£¬£¬£¬ÊÇÃÀ¹úʳÎïÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨FDA£©Åú×¼µÄÊ׸öÓÃÓÚ¸´·¢»òÄÑÖÎÐÔAMLµÄFLT3ÒÖÖÆ¼Á£¬£¬£¬£¬£¬ÔÚÃÀ¹ú¡¢ÈÕ±¾¡¢Å·Ã˲¿·Ö¹ú¼Ò¼°ÆäËû¹ú¼ÒºÍµØÇøÊµÏÖÁË»¼Õ߿ɼ°¡£¡£¡£¹ú¼ÊȨÍþҽѧÆÚ¿¯¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·Ôø½ÒÏþ¹ýÆÀ¹ÀXOSPATA IIIÆÚADMIRALÊÔÑéµÄЧ¹û4£¬£¬£¬£¬£¬Ð§¹ûÏÔʾXOSPATAÖÎÁƵϼÕßµÄ×ÜÉúÑļ°»º½âÂʾùÏÔÖø¸ßÓÚ½ÓÊܱê×¼Õü¾ÈÐÔ»¯ÁƵϼÕß¡£¡£¡£
2020Äê3ÔÂ24ÈÕ£¬£¬£¬£¬£¬¼ªÈðÌæÄáÔÚÖйúÌá½»ÉÏÊÐÉêÇ룬£¬£¬£¬£¬7ÔÂ21ÈÕ¼´»ñµÃÓÅÏÈÉóÆÀ×ʸñ£¬£¬£¬£¬£¬11ÔÂ19ÈÕ±»ÄÉÈëµÚÈýÅúÁÙ´²¼±Ðè¾³ÍâÐÂÒ©Ãûµ¥¡£¡£¡£ÔÚ¹ú¼Ò½ÓÊÜÒ©Æ·¾³ÍâÁÙ´²ÊÔÑéÊý¾Ý¡¢¼ò»¯¾³ÍâÒÑÉÏÊÐÒ©Æ·Èë¿ÚÉóÅúµÄÅä¾°Ï£¬£¬£¬£¬£¬XOSPATAÓÐÍû¼ÓËÙÔÚÖйúµÄ»ñÅúÉÏÊУ¬£¬£¬£¬£¬ÔçÈÕΪº£ÄÚFLT3Í»±äµÄAML»¼Õß´øÀ´Í»ÆÆÐÔÖÎÁƼƻ®¡£¡£¡£
ÔÙ¶ÈЯÊÖÉÏàÖú£¬£¬£¬£¬£¬¹²ÍØÐÂÌØÒ©¿É¼°ÐÔ
ÊÜÕïÁƼƻ®¡¢¼²²¡ÈÏ֪ˮһÂÉÒòËØµÄÓ°Ï죬£¬£¬£¬£¬ÍâÑóÁ¢ÒìÒ©½øÈëÖйúÊг¡£¡£¡£¬£¬£¬£¬£¬ÔõÑùÔÚרÀûÆÚÄÚ¿ìËÙ½«²úÆ·½á¹¹µ½ÖÕ¶ËÊг¡£¡£¡£¬£¬£¬£¬£¬ÊµÊ±Îª»¼ÕßÌṩ¼²²¡ÖÎÁƽâ¾ö¼Æ»®£¬£¬£¬£¬£¬ÊÇÒ©Æ·»ñÅúÉÏÊкóÃæÁÙµÄØ½´ý½â¾öµÄÎÊÌâ¡£¡£¡£
°²Ë¹Ì©À´×÷ΪȫÇòÁìÏȵÄÁ¢ÒìÐÍÖÆÒ©ÆóÒµ£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚ½«Á¢Òì¿ÆÑ§×ª±äΪҽÁƽâ¾ö¼Æ»®£¬£¬£¬£¬£¬ÎªÈ«Çò»¼Õß´øÀ´¼ÛÖµºÍÏ£Íû¡£¡£¡£ÖйúÊг¡µÄ¿ªÍؽṹ£¬£¬£¬£¬£¬Êǰ²Ë¹Ì©À´È«ÇòÕ½ÂÔÖеÄÖ÷Òª×é³É²¿·Ö¡£¡£¡£
×÷ΪÖйúרҵµÄµÚÈý·½Ò½Ò©ÉÌÒµ»¯Æ½Ì¨£¬£¬£¬£¬£¬bwin±ØÓ®Í¨¹ýÈ«ÇþµÀÁýÕÖ¡¢¶àÆ·ÀàÐͬÒÔ¼°Êý×Ö»¯ÓªÏúµÄ²î±ð»¯ÄÜÁ¦£¬£¬£¬£¬£¬¾ßÓÐΪÉÏÓι¤ÒµÆóÒµÌṩȫÇþµÀ½â¾ö¼Æ»®µÄʵÁ¦¡£¡£¡£´Ëǰ£¬£¬£¬£¬£¬°²Ë¹Ì©À´ÒÑÓëbwin±ØÓ®Ç£ÊÖÏàÖú£¬£¬£¬£¬£¬Æì϶à¸öÔÑÐÒ©¾ù»ñµÃÁ˺£ÄÚÊг¡·Ý¶îµÄÏÔÖøÌáÉý¡£¡£¡£
¾ÝÏàʶ£¬£¬£¬£¬£¬´Ë´ÎÏàÖúÒâÏòÇ©Êðºó£¬£¬£¬£¬£¬Ë«·½Ç¨¾ÍXOSPATAµÄÈë¿Ú±£Ë°Í¨¹Ø¡¢²Ö´¢ÎïÁ÷µÈÒ»Ì廯ЧÀÍ£¬£¬£¬£¬£¬ÒÔ¼°È«ÇþµÀÉÌÒµ»¯Æ½Ì¨½â¾ö¼Æ»®¿ªÕ¹½øÒ»²½µÄ̽ÌÖ£¬£¬£¬£¬£¬ÌáÉýÖйúAML»¼ÕßµÄÓÃÒ©¿É¼°ÐÔ¡£¡£¡£
×÷Ϊºã¾ÃµÄÏàÖúͬ°é£¬£¬£¬£¬£¬°²Ë¹Ì©À´¶Ôbwin±ØÓ®ÉÌÒµ»¯Æ½Ì¨µÄ¼ÛÖµºÍÓÅÊÆ³äÂúÐÅÐÄ£¬£¬£¬£¬£¬´Ë´ÎÓëbwin±ØÓ®ÔÙ¶ÈЯÊÖ£¬£¬£¬£¬£¬½«¸ÄÉÆÖйúAMLÁìÓòδ±»Öª×ãµÄÖÎÁÆÐèÇ󣬣¬£¬£¬£¬Îª»¼Õß¼°Æä¼ÒÈË´øÀ´ÐµÄÏ£Íû¡£¡£¡£
Çൺ¿Ú°¶Ö±´ï£¬£¬£¬£¬£¬Íƶ¯¡°Ò»´øÒ»Æð¡±¿µ½¡¾Ã³ÏàÖú
ÓëÈÕ±¾¸ôº£ÏàÍûµÄÇൺ£¬£¬£¬£¬£¬¾ßÓÐÉî¶ÈÈÚÈë¡°Ò»´øÒ»Æð¡±µÄÇøÎ»ÓÅÊÆ¡£¡£¡£2019Ä꣬£¬£¬£¬£¬ÖÐÑëÖÜÈ«ÉˢÐÂίԱ»áµÚ¾Å´Î¾Û»áÉóÒéͨ¹ýÁË¡¶Öйú¡ªÉϺ£ÏàÖú×éÖ¯µØ·½¾Ã³ÏàÖúÊ÷Ä£Çø½¨Éè×ÜÌ弯»®¡·£¬£¬£¬£¬£¬ÒªÔÚÉϺÏÊ÷Ä£ÇøÇൺ´òÔì¡°Ò»´øÒ»Æð¡±¹ú¼ÊÏàÖúÐÂÆ½Ì¨£¬£¬£¬£¬£¬Íƶ¯¹¤¾ßË«Ïò»¥¼Ã¡¢Â½º£ÄÚÍâÁª¶¯µÄ¿ª·ÅÃûÌᣡ£¡£×÷Ϊפ×ãÓÚÇൺ±¾ÍÁµÄÒ½Ò©ÐÐÒµÁúÍ·ÆóÒµ£¬£¬£¬£¬£¬bwin±ØÓ®ÏȺóÓëÈÕ±¾¶à¼Ò×ÅÃûÒ©Æó½¨ÉèÏàÖú£¬£¬£¬£¬£¬Æð¾¢ÈÚÈë¡°Ò»´øÒ»Æð¡±¹ú¼ÊÏàÖúÐÂÆ½Ì¨µÄÕ½ÂÔ¡£¡£¡£
ÖµµÃ×¢ÖØµÄÊÇ£¬£¬£¬£¬£¬ÔÚ´Ë´ÎÓ밲˹̩À´µÄÏàÖúÖУ¬£¬£¬£¬£¬ÓµÓÐÍêÉÆµÄÒ©Æ·Èë¿Ú×ÊÖʼ°º£¹ØAEOÈÏÖ¤×ÊÖʵÄbwin±ØÓ®£¬£¬£¬£¬£¬ÏÔʾ³öÆäǿʢµÄÍâÑóÒ©Æ·Èë¿ÚӪҵʵÁ¦¡£¡£¡£ÎÞÂÛÊÇÈë¿Ú±£Ë°Í¨¹Ø¡¢ÀäÁ´¿â·¿ÕվɸßЧÎïÁ÷ÅäËÍ£¬£¬£¬£¬£¬¶¼ÓÐרҵµÄÈë¿Ú²Ù×÷ÍŶӾÙÐÐÈ«Á÷³ÌЧÀÍ£¬£¬£¬£¬£¬ÎªÍâÑóÒ©Æ·Êèͨ¹ú¼ÊÎïÁ÷ͨµÀ¡£¡£¡£ÔÚ¾ÓÉÊ×´ÎÈë¿ÚÁ÷³Ìºó£¬£¬£¬£¬£¬XOSPATA±ã¿Éͨ¹ý¿ÕÔË·½·¨£¬£¬£¬£¬£¬Ö±½Ó´ÓÈÕ±¾ÓÉÇൺ¿Ú°¶½øÈëÖйú£¬£¬£¬£¬£¬ÌáÉýЧÂÊ£¬£¬£¬£¬£¬½µµÍ±¾Ç®¡£¡£¡£
˳Ӧ¿µ½¡¹¤ÒµÉú³¤Ç÷ÊÆ£¬£¬£¬£¬£¬bwin±ØÓ®×÷Ϊ¹¤ÒµÁ´ÏÂÓÎרҵµÄµÚÈý·½ÉÌÒµ»¯Æ½Ì¨£¬£¬£¬£¬£¬ÖúÁ¦ÐÐÒµÓÅ»¯×ÊÔ´£¬£¬£¬£¬£¬ÌáÉýЧÂÊ¡£¡£¡£½üÄêÀ´£¬£¬£¬£¬£¬bwin±ØÓ®ÉÌÒµ»¯Æ½Ì¨ÎüÒýÁËÖÚ¶àÏàÖúͬ°é£¬£¬£¬£¬£¬ÂõÀ¶¡¢Î÷°²ÑîÉ¡¢ÎäÌï¡¢½ÜÌØ±´ÁÖ¡¢ÑÅÅàµÈº£ÄÚÍâÖ÷Á÷Ò©Æó¶¼Óëbwin±ØÓ®¸æ¿¢ÁËÎȹÌÏàÖú¹ØÏµ¡£¡£¡£³Ð¼ÌΪȫÉç»áÌṩ¸üºÃµÄÒ½ÁÆ¿µ½¡²úÆ·ºÍЧÀ͵ÄʹÃü£¬£¬£¬£¬£¬bwin±ØÓ®½«Ò»Á¬Ê©Õ¹ÉÌÒµ»¯Æ½Ì¨µÄרҵÄÜÁ¦£¬£¬£¬£¬£¬´î½¨¸ü¶àÍâÑóÒ©ÆóÓ뺣ÄÚÊг¡ÅþÁ¬µÄ¡°ÇÅÁº¡±£¬£¬£¬£¬£¬ÈÃÖйúµÄÀÏÀèÃñÄÜÓÃÉϹú¼ÊÆ·ÖʵĺÃÒ©¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1 GLOBOCAN Cancer Today Database, International Agency for Research on Cancer, World Health Organisation. Population Fact Sheets in 2018.
2 GLOBOCAN Cancer Today Database, International Agency for Research on Cancer, World Health Organisation. Population Fact Sheets in 2018.
3 American Cancer Society. Risk Factors for Acute Myeloid Leukemia (AML).
4 Perl A, Martinelli G, Cortes J, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019; 381:1728-40.
ÆäËûÐÂÎÅ








